Investor Relations

Investor Relations Home

Stock Information
Corporate Profile

Foamix Pharmaceuticals is a specialty pharmaceutical company, committed to addressing unmet needs of patients by bringing innovative solutions to the field of dermatology. The company is in late-stage clinical development of two lead products based on the company’s first-in-class topical Minocycline Foam: FMX101, for the treatment of moderate-to-severe acne, and FMX102, for the treatment of impetigo. Having completed Phase II clinical trials of these product candidates, the company expects ... More >>

Recent NewsMore >>
DateTitle 
05/09/17Foamix Reports First Quarter 2017 Financial Results and Provides Business UpdatePrinter Friendly Version
05/01/17Foamix Pharmaceuticals Announces Plans for Additional Phase 3 Trial for FMX101 in Moderate to Severe AcnePrinter Friendly Version
04/27/17Foamix Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Health Care ConferencePrinter Friendly Version
04/26/17Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for Wednesday, May 10Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Foamix Pharmaceuticals Ltd posts new information to the site. Just enter your e-mail address and click Submit.